Cargando…

COVID-19–Related Outcomes in Primary Mitochondrial Diseases: An International Study

BACKGROUND AND OBJECTIVES: To identify factors associated with severe coronavirus disease 2019 (COVID-19), defined by hospitalization status, in patients with primary mitochondrial diseases (PMDs), thereby enabling future risk stratification and informed management decisions. METHODS: We undertook a...

Descripción completa

Detalles Bibliográficos
Autores principales: Pizzamiglio, Chiara, Machado, Pedro M., Thomas, Rhys H., Gorman, Gráinne S., McFarland, Robert, Hanna, Michael G., Pitceathly, Robert D. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992603/
https://www.ncbi.nlm.nih.gov/pubmed/35190464
http://dx.doi.org/10.1212/WNL.0000000000200240
_version_ 1784683763208290304
author Pizzamiglio, Chiara
Machado, Pedro M.
Thomas, Rhys H.
Gorman, Gráinne S.
McFarland, Robert
Hanna, Michael G.
Pitceathly, Robert D. S.
author_facet Pizzamiglio, Chiara
Machado, Pedro M.
Thomas, Rhys H.
Gorman, Gráinne S.
McFarland, Robert
Hanna, Michael G.
Pitceathly, Robert D. S.
author_sort Pizzamiglio, Chiara
collection PubMed
description BACKGROUND AND OBJECTIVES: To identify factors associated with severe coronavirus disease 2019 (COVID-19), defined by hospitalization status, in patients with primary mitochondrial diseases (PMDs), thereby enabling future risk stratification and informed management decisions. METHODS: We undertook a cross-sectional, international, registry-based study. Data were extracted from the International Neuromuscular COVID-19 Database and collected between May 1, 2020, and May 31, 2021. The database included subjects with (1) PMD diagnosis (any age), clinically/histopathologically suspected and/or genetically confirmed; and (2) COVID-19 diagnosis classified as “confirmed”, “probable”, or “suspected” based on World Health Organization definitions. The primary outcome was hospitalization because of COVID-19. We collected demographic information, smoking status, coexisting comorbidities, outcomes after COVID-19 infection, and PMD genotype-phenotype. Baseline status was assessed using the modified Rankin scale (mRS) and the Newcastle Mitochondrial Disease Adult Scale (NMDAS). RESULTS: Seventy-nine subjects with PMDs from 10 countries were included (mean age 41.5 ± 18 years): 25 (32%) were hospitalized, 48 (61%) recovered fully, 28 (35%) improved with sequelae, and 3 (4%) died. Statistically significant differences in hospitalization status were observed in baseline status, including the NMDAS score (p = 0.003) and mRS (p = 0.001), presence of respiratory dysfunction (p < 0.001), neurologic involvement (p = 0.003), and more than 4 comorbidities (p = 0.002). In multivariable analysis, respiratory dysfunction was independently associated with COVID-19 hospitalization (odds ratio, 7.66; 95% CI, 2–28; p = 0.002). DISCUSSION: Respiratory dysfunction is an independent risk factor for severe COVID-19 in PMDs while high disease burden and coexisting comorbidities contribute toward COVID-19–related hospitalization. These findings will enable risk stratification and informed management decisions for this vulnerable population.
format Online
Article
Text
id pubmed-8992603
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-89926032022-04-11 COVID-19–Related Outcomes in Primary Mitochondrial Diseases: An International Study Pizzamiglio, Chiara Machado, Pedro M. Thomas, Rhys H. Gorman, Gráinne S. McFarland, Robert Hanna, Michael G. Pitceathly, Robert D. S. Neurology Clinical/Scientific Note BACKGROUND AND OBJECTIVES: To identify factors associated with severe coronavirus disease 2019 (COVID-19), defined by hospitalization status, in patients with primary mitochondrial diseases (PMDs), thereby enabling future risk stratification and informed management decisions. METHODS: We undertook a cross-sectional, international, registry-based study. Data were extracted from the International Neuromuscular COVID-19 Database and collected between May 1, 2020, and May 31, 2021. The database included subjects with (1) PMD diagnosis (any age), clinically/histopathologically suspected and/or genetically confirmed; and (2) COVID-19 diagnosis classified as “confirmed”, “probable”, or “suspected” based on World Health Organization definitions. The primary outcome was hospitalization because of COVID-19. We collected demographic information, smoking status, coexisting comorbidities, outcomes after COVID-19 infection, and PMD genotype-phenotype. Baseline status was assessed using the modified Rankin scale (mRS) and the Newcastle Mitochondrial Disease Adult Scale (NMDAS). RESULTS: Seventy-nine subjects with PMDs from 10 countries were included (mean age 41.5 ± 18 years): 25 (32%) were hospitalized, 48 (61%) recovered fully, 28 (35%) improved with sequelae, and 3 (4%) died. Statistically significant differences in hospitalization status were observed in baseline status, including the NMDAS score (p = 0.003) and mRS (p = 0.001), presence of respiratory dysfunction (p < 0.001), neurologic involvement (p = 0.003), and more than 4 comorbidities (p = 0.002). In multivariable analysis, respiratory dysfunction was independently associated with COVID-19 hospitalization (odds ratio, 7.66; 95% CI, 2–28; p = 0.002). DISCUSSION: Respiratory dysfunction is an independent risk factor for severe COVID-19 in PMDs while high disease burden and coexisting comorbidities contribute toward COVID-19–related hospitalization. These findings will enable risk stratification and informed management decisions for this vulnerable population. Lippincott Williams & Wilkins 2022-04-05 /pmc/articles/PMC8992603/ /pubmed/35190464 http://dx.doi.org/10.1212/WNL.0000000000200240 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical/Scientific Note
Pizzamiglio, Chiara
Machado, Pedro M.
Thomas, Rhys H.
Gorman, Gráinne S.
McFarland, Robert
Hanna, Michael G.
Pitceathly, Robert D. S.
COVID-19–Related Outcomes in Primary Mitochondrial Diseases: An International Study
title COVID-19–Related Outcomes in Primary Mitochondrial Diseases: An International Study
title_full COVID-19–Related Outcomes in Primary Mitochondrial Diseases: An International Study
title_fullStr COVID-19–Related Outcomes in Primary Mitochondrial Diseases: An International Study
title_full_unstemmed COVID-19–Related Outcomes in Primary Mitochondrial Diseases: An International Study
title_short COVID-19–Related Outcomes in Primary Mitochondrial Diseases: An International Study
title_sort covid-19–related outcomes in primary mitochondrial diseases: an international study
topic Clinical/Scientific Note
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992603/
https://www.ncbi.nlm.nih.gov/pubmed/35190464
http://dx.doi.org/10.1212/WNL.0000000000200240
work_keys_str_mv AT pizzamigliochiara covid19relatedoutcomesinprimarymitochondrialdiseasesaninternationalstudy
AT machadopedrom covid19relatedoutcomesinprimarymitochondrialdiseasesaninternationalstudy
AT thomasrhysh covid19relatedoutcomesinprimarymitochondrialdiseasesaninternationalstudy
AT gormangrainnes covid19relatedoutcomesinprimarymitochondrialdiseasesaninternationalstudy
AT mcfarlandrobert covid19relatedoutcomesinprimarymitochondrialdiseasesaninternationalstudy
AT hannamichaelg covid19relatedoutcomesinprimarymitochondrialdiseasesaninternationalstudy
AT pitceathlyrobertds covid19relatedoutcomesinprimarymitochondrialdiseasesaninternationalstudy
AT covid19relatedoutcomesinprimarymitochondrialdiseasesaninternationalstudy